Navigation Links
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
Date:12/10/2007

known risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Preliminary results may not be confirmed upon final analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Vidaza and MGCD0103 may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data from this or other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the investment community.


'/>"/>
SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HealthDay Reporter , MONDAY, July 28, 2014 (HealthDay ... may be able to take hormone replacement therapy soon after ... to a new study. Previous studies, including the large-scale ... effects on the heart. But, many of those women were ... past menopause. In this new study, researchers wanted ...
(Date:7/29/2014)... Kelly and Zhi Sheng , assistant professors ... recently received a grant from the Commonwealth Health ... effort that may lead to new treatment approaches. , ... , The grant will fund a two-year project to ... the BRCA1 gene. This type of cancer often has ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The global ... 9,542.3 million by 2020, growing at an estimated CAGR ... new study by Grand View Research, Inc. Introduction of ... devices by the geriatric population, along with increase in ... the major drivers of this market. In addition, presence ...
(Date:7/29/2014)... July 29, 2014 On Friday, the ... declaring the week of October 12-18, 2014, as "National ... management in improving healthcare outcomes for patients. The resolution ... John Boozman (R-AR), with support by the Case Management ... to honor case management professionals for their contributions to ...
(Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
Breaking Medicine News(10 mins):Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2
... men generally have lower prostate specific antigen levels than men ... the PSA test may not be as good at identifying ... 2,800 men with no evidence of prostate cancer. Results showed ... across all age groups and throughout all races. A study ...
... is effective in reducing the risk of death following a ... attack // find researchers according to latest research. ,In ... reviparin on the composite outcome of death, heart attack, and ... was reduced from 11 percent of patients in the placebo ...
... broiled fish, such as tuna, may lower stroke risk ... adults 65 and older. Study participants answered food-frequency questionnaires ... years. ,Results showed 626 of the participants experienced ... broiled or baked fish one- to four-times per week ...
... with a long-acting beta2-agonist (formoterol) can actually provide significant ... high doses of inhaled steroid, say researchers according to ... of various combinations of medicine on asthma symptoms in ... were analyzed. The patients were divided into three treatment ...
... over whether hormone replacement therapy is safe and effective ... the pros and cons of this controversial therapy. ... five years. All the women studied were 50 years ... others did not.Results showed women free of menopausal symptoms ...
... The use of alternative or complementary therapies have increased ... people using // at least one form of alternative ... biofeedback, yoga, hypnosis, acupuncture, chiropractic care, and high-dose vitamins. ... their own survey taken in 1997 to the National ...
Cached Medicine News:
(Date:7/29/2014)... , July 29, 2014 Today, Frost ... Frost & Sullivan Best Practices Award for Customer ... a cloud-based platform that connects digital health application ... as providers, pharmaceutical companies, prevention and wellness companies, ... Each year, Frost & Sullivan presents ...
(Date:7/29/2014)...   , First patient begins treatment ... safety of MSB0010718C in patients with metastatic Merkel cell carcinoma ... cancer lacking effective treatments   MSB0010718C is also currently ... for the treatment of solid tumors that aims to recruit ... of Merck KGaA, Darmstadt, Germany , today ...
(Date:7/28/2014)... (NASDAQ: LMNX ) today announced financial results ... and operating highlights include the following: , ... percent increase over the second quarter of 2013. ... 9 percent increase over the second quarter of 2013.  ... which included 148 LX systems, 96 MAGPIX systems, and ...
Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
... Reportlinker.com announces that a new market research ... Cancer Pain Therapeutics - ... http://www.reportlinker.com/p0546769/Cancer-Pain-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
... YORK, June 1, 2011 ... market research report is available ... Interventional Neurology - ... and Market Forecasts to 2017 ...
Cached Medicine Technology:Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12
... Forma 1400 Series ... specifically to revolutionize working ... cabinet. The most comfortable, ... Class II cabinet on ...
... The Premier 12 Holter Analysis Kit ... QT Dispersion with other powerful DMS Holter ... 24-hour TWA analysis possible in less than ... actual TWA, for visual verification and validation. ...
... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...
... patient will be more comfortable, and you ... stabilization more secure and to avoid the ... untying of twill ties, consider the Dale® ... neonate/infant sizes, the narrow fastener tabs of ...
Medicine Products: